Making paralysis a thing of the past!

Spinal cord injuries, mostly of traumatic origin, are complex multi-factorial pathologies that currently impact ca. 250’000 new patients yearly worldwide, leaving them with permanent neurological impairments.

Spinal cord injury has still unmet clinical needs: present tentative therapies indeed target at best only single components of this multi-factorial complex pathology.

In this complex framework, Regenera proposes its proprietary innovative combined biomaterial and stem cells paradigm to counteract the cascade of events that follow after cord lesion, to be applied after standard anti-inflammatory therapy during post traumatic stabilization surgery: trophic support to tissue plasticity will be provided by locally grafting, outside lesioned parenchyma, autologous stem cells duly hosted into its proprietary innovative injectable resorbable hydrogel (SpinoSave®). Using the paracrine effect of the stem cells, the damaged tissue will be progressively led toward (self) regeneration to achieve cord functionality restoration.

Our in vivo model studies already showed improved motor and sensory performances up to 60%.

View our most relevant publications here